Search

Your search keyword '"Ola Landgren"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Ola Landgren" Remove constraint Author: "Ola Landgren" Journal clinical lymphoma myeloma and leukemia Remove constraint Journal: clinical lymphoma myeloma and leukemia
30 results on '"Ola Landgren"'

Search Results

1. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

4. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma

6. P-171: African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients

8. P-178: A pilot plant based dietary intervention in MGUS and SMM is feasible and associated with reduction in insulin and leptin levels

9. OAB-014: Chemotherapy signatures reveal the evolutionary history of post-melphalan myeloid neoplasm

10. P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?

11. P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets

12. Next Questions: Multiple Myeloma

14. Depth of Response and Outcomes by Initial Therapy Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

15. Practice Patterns with Focal Progression on Daratumumab Therapy

16. The Road to Treating Smoldering Multiple Myeloma

17. Multiple Myeloma and Second Malignancies

18. Why Clinicians are Not Relying on Evidence from Indirect Comparison Studies Evaluating Comparative Efficacy of Interventions for Relapsed or Refractory Multiple Myeloma: A Critical Review

19. Fractures and Survival in Multiple Myeloma: Results from a Population-Based Study

20. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)

21. Peripheral neuropathy and monoclonal gammopathy of undetermined significance: A population-based study including 15,351 cases and 58,619 matched controls

22. Multiple myeloma and comorbidity: a population-based study

23. Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma

24. Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia

25. Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

26. Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

27. Improvement of Response for Multiple Myeloma patients on Lenalidomide Maintenance after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT)

28. What Causes Waldenström's Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?

29. Centaurus (JNJ5467414SMM2001): A Randomized Phase II Trial to Evaluate Three Daratumumab (DARA) Dose Schedules in Smoldering Multiple Myeloma (SMM)

30. 3.16 Increased Incidence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Patients with Merkel Cell Carcinoma in Israel

Catalog

Books, media, physical & digital resources